Lasa Supergenerics Limited (LASA)

Loading page…

Lasa Supergenerics Limited (LASA) · mywealthgrid

About

Lasa Supergenerics Limited operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹28 Cr

P/E

—

P/B

0.6×

Dividend yield

ROE

-51.1%

ROCE

-51.1%

Debt / equity

0.2

OPM

-113%

EPS (TTM)

₹-3.3

Book value

₹9.9

52-week high

—

52-week low

—

2,217 historical price candles were omitted because the exchange source has not been verified.

Only one verified price point is available. The trend chart will appear when more exchange closes are stored.

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of -29.2% (3-yr avg)
−Revenue shrank over the last 5 years (-34.1% a year)
−Weak interest coverage of -87.7×

Research score

Structured signal from quality, growth, valuation and momentum.

39/100

Business quality: 18
Growth: 0
Valuation: 100

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	218	246	170	167	202	137	130	104	142	25
COGS	131	172	-68	95	112	91	106	75	106	24
Gross profit	87	74	—	73	90	46	23	29	36	1
	42	33	226	43	43	30	30	27	30	30
	46	41	11	30	47	16	-7	2	6	-28
OPM %	20.9%	16.8%	6.6%	17.9%	23.3%	11.4%	-5.1%	2.1%	4.4%	-113%
Depreciation	8	18	19	17	16	14	13	11	12	6
Interest	12	11	12	8	2	0	4	2	3	0
	28	3	4	0	0	-8	-18	-9	-11	0
Profit before tax	2	15	-16	4	30	-7	-42	-19	-19	-35
Tax	-0	3	-4	1	8	-1	-4	3	-5	-1
Tax %	-10.3%	19%	-24.7%	16.9%	25.1%	-21.4%	-8.7%	13.7%	-23.9%	-1.5%
	2	12	-12	4	23	-5	-39	-22	-15	-34
PAT margin %	1.1%	5%	-7.1%	2.2%	11.3%	-3.9%	-29.8%	-20.8%	-10.4%	-135.6%
EPS (₹)	1.2	—	-5.3	1.3	5.6	-1.3	-15.4	-4.3	-3	-6.8
EPS adjusted (₹)	—	—	—	0.9	5.6	-1.3	-7.7	-4.3	-3	-6.8
	0%	—	—	0%	4.5%	—	—	—	—	—
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	41	41	41	50	50	50	50
Reserves	—	118	108	68	47	34	-0
Minority interest	—	0	—	0	—	—	—
	—	0	0	0	22	3	10
	—	49	51	46	32	15	7
Total equity & liabilities	—	208	199	164	151	102	66
	152	143	122	119	110	68	38
CWIP	—	0	5	5	3	0	0
Investments	—	0	0	0	0	0	0
	—	65	73	40	39	33	28
Total assets	—	208	199	164	151	102	66

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-3	40	41	14	41	10	-34	2	-3	-23
	0	-44	-7	-2	-4	-3	2	-0	8	0
	0	4	-33	-10	-36	-0	4	-2	-6	0
Net cash flow	-3	0	-0	2	1	7	-28	-0	-0	-23
Free cash flow	—	—	—	—	35	8	-38	1	-3	-23
CFO / Operating profit %	-6.6%	97.6%	366.3%	45.5%	87.5%	67.1%	—	98.6%	-45%	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	43.4%	44.5%	33.4%	18.1%	27.9%	25.5%	5.2%
EBITDA margin %	6.6%	17.9%	23.3%	11.4%	-5.1%	2.1%	4.4%	-113%
EBIT margin %	-4.8%	7.5%	15.5%	1.2%	-15.4%	-8.1%	-4.2%	-136.9%
PAT margin %	-7.1%	2.2%	11.3%	-3.9%	-29.8%	-20.8%	-10.4%	-135.6%
Working capital
Receivable days	—	—	27	49	7	13	4	1
Inventory days	—	—	56	46	48	92	84	28
Payable days	—	—	41	63	32	68	35	32
NWC days	—	—	41	32	22	37	53	-4
Leverage
Current ratio	—	—	1.59	1.65	0.92	0.78	1.9	0.62
Debt to EBITDA	—	—	0	0	—	10.18	0.41	—
Debt to equity	—	—	0	0	0	0.23	0.03	0.2
Interest coverage	-0.3	1.6	16	42.5	-4.4	-4.4	-0.4	-87.7
Asset turnover	—	—	0.97	0.69	0.79	0.69	1.4	0.38
Return ratios
Return on assets %	—	—	11%	-2.7%	-23.6%	-14.4%	-14.5%	-51.4%
Return on capital employed %	—	—	18.8%	1.1%	-13.2%	-7.5%	-1.1%	-51.1%
Return on equity %	—	—	14.3%	-3.6%	-32.7%	-22.5%	-17.6%	-68.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	53.65%	53.65%	53.65%	53.65%	53.65%	53.65%	53.65%	53.65%	53.65%	53.65%	53.65%	53.65%
FII	0%	0%	0.01%	0.12%	0%	0.01%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	46.35%	46.35%	46.34%	46.23%	46.35%	46.34%	46.35%	46.35%	46.35%	46.35%	46.35%	46.35%
No. of shareholders	—	—	—	—	—	—	—	—	—	28,656	28,120	27,702

Promoter holding up 0 percentage points since Jun 2023.

29 deals · 23 Aug 2021 – 8 Sept 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
8 Sept 2025	AMIT KUMAR JAIN HUF	Bulk	NSE	Buy	3,98,113	₹10.57	₹0.42 Cr
8 Sept 2025	AMIT KUMAR JAIN HUF	Bulk	NSE	Sell	2,24,606	₹10.65	₹0.24 Cr
22 May 2025	BNP ENTERPRISES	Bulk	NSE	Sell	2,84,542	₹17.28	₹0.49 Cr
1 Jan 2024	MANBHUPINDER SINGH ATWAL	Bulk	NSE	Sell	2,80,000	₹28.38	₹0.79 Cr
27 Dec 2023	MANBHUPINDER SINGH ATWAL	Bulk	NSE	Buy	3,00,000	₹32.80	₹0.98 Cr
17 Feb 2023	PALAK INTERMEDIATES PRIVATE LIMITED	Bulk	NSE	Sell	2,70,838	₹29.96	₹0.81 Cr
17 Feb 2023	PALAK INTERMEDIATES PRIVATE LIMITED	Bulk	NSE	Buy	2,70,838	₹30.59	₹0.83 Cr
16 Feb 2023	PALAK INTERMEDIATES PRIVATE LIMITED	Bulk	NSE	Sell	7,73,407	₹29.13	₹2.25 Cr
16 Feb 2023	PALAK INTERMEDIATES PRIVATE LIMITED	Bulk	NSE	Buy	7,73,407	₹29.06	₹2.25 Cr
21 Sept 2022	SKSE SECURITIES LTD	Bulk	NSE	Sell	3,27,891	₹41.55	₹1.36 Cr

1–10 of 29

1 / 3

Mr. Omkar Pravin HerlekarExecutive Director-Chairperson-MD
Mr. Ganesh Suresh PotdarExecutive Director-MD
Mr. Ketan Bhau SongalNon-Executive - Independent Director
Mr. Pravin Gadalya LachakeNon-Executive - Independent Director
Mr. Yogesh Hari UghadaNon-Executive - Independent Director
Ms. Rekha Hemant WakhNon-Executive - Independent Director
Mrs. Varsha Pravin JoshiChief Financial Officer
Mrs. Mitti JainCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Lasa Supergenerics Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

2

Final dividend16 Sept 2022 · ex-date₹0.25
Final dividend15 Sept 2021 · ex-date₹0.25

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

10 announcementsExport CSV

14 Aug 2026, 6:56 pmCompany Update

Integrated Filing For Quarter Ended June 30, 2026

General PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	43.4%	44.5%	33.4%	18.1%	27.9%	25.5%	5.2%
EBITDA margin %	6.6%	17.9%	23.3%	11.4%	-5.1%	2.1%	4.4%	-113%
EBIT margin %	-4.8%	7.5%	15.5%	1.2%	-15.4%	-8.1%	-4.2%	-136.9%
PAT margin %	-7.1%	2.2%	11.3%	-3.9%	-29.8%	-20.8%	-10.4%	-135.6%
Working capital
Receivable days	—	—	27	49	7	13	4	1
Inventory days	—	—	56	46	48	92	84	28
Payable days	—	—	41	63	32	68	35	32
NWC days	—	—	41	32	22	37	53	-4
Leverage
Current ratio	—	—	1.59	1.65	0.92	0.78	1.9	0.62
Debt to EBITDA	—	—	0	0	—	10.18	0.41	—
Debt to equity	—	—	0	0	0	0.23	0.03	0.2
Interest coverage	-0.3	1.6	16	42.5	-4.4	-4.4	-0.4	-87.7
Asset turnover	—	—	0.97	0.69	0.79	0.69	1.4	0.38
Return ratios
Return on assets %	—	—	11%	-2.7%	-23.6%	-14.4%	-14.5%	-51.4%
Return on capital employed %	—	—	18.8%	1.1%	-13.2%	-7.5%	-1.1%	-51.1%
Return on equity %	—	—	14.3%	-3.6%	-32.7%	-22.5%	-17.6%	-68.7%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
14 Aug 2026, 6:56 pm	Company Update General	Integrated Filing For Quarter Ended June 30, 2026	PDF
14 Aug 2026, 6:23 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of Board Meeting For The Quarter Ended June 30, 2026	PDF

Lasa Supergenerics Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends2

Board meetings1

Announcements

Dividends2

Board meetings1

Ratio timeline

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

2

1

2

1